PlainRecalls
FDA Drug Moderate Class II Ongoing

Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000 count (NDC 57237-018-99) bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ

Reported: January 15, 2025 Initiated: December 30, 2024 #D-0188-2025

Product Description

Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000 count (NDC 57237-018-99) bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ

Reason for Recall

CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.

Details

Units Affected
42,527 bottles
Distribution
Nationwide
Location
East Brunswick, NJ

Frequently Asked Questions

What product was recalled?
Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000 count (NDC 57237-018-99) bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ. Recalled by Rising Pharma Holding, Inc.. Units affected: 42,527 bottles.
Why was this product recalled?
CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 15, 2025. Severity: Moderate. Recall number: D-0188-2025.